SCHEMBL7654043

SCHEMBL7654043

CCCCC(NC(=O)c1ccc(NS(=O)(=O)c2ccc3ccccc3c2)cc1)C(=O)CNC(C)=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.54
LMNA P02545 1/20 0.54
GAA P10253 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
HDAC1 Q13547 2/20 0.51
HDAC3 O15379 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC10 Q969S8 1/20 0.51
HDAC11 Q96DB2 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
HDAC9 Q9UKV0 1/20 0.51
HDAC5 Q9UQL6 1/20 0.51
PLAU P00749 3/20 0.48
ATM Q13315 1/20 0.45
CA2 P00918 2/20 0.45
GPR27 Q9NS67 1/20 0.45
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7665000 0.93 ALDH1A1 (0.52) ALDH1A1LMNAGAASMN1; SMN2HDAC1
SCHEMBL7658785 0.91 ALDH1A1 (0.45) ALDH1A1LMNAGAASMN1; SMN2HDAC1
SCHEMBL7425669 0.89 ALDH1A1 (0.52) ALDH1A1LMNAGAASMN1; SMN2HDAC1
SCHEMBL7682470 0.89 ALDH1A1 (0.51) ALDH1A1LMNAGAASMN1; SMN2HDAC1
SCHEMBL7689558 0.86 ALDH1A1 (0.55) ALDH1A1LMNAGAASMN1; SMN2HDAC1
SCHEMBL7659849 0.86 AKR1C3 (0.47) ALDH1A1LMNAGAASMN1; SMN2PLAU
SCHEMBL7668656 0.84 KMT2A (0.52) HDAC1HDAC3HDAC2PLAUKMT2A
SCHEMBL7665441 0.81 EGFR (0.46) LMNASMN1; SMN2HDAC1HDAC3HDAC4
SCHEMBL7427436 0.81 AKR1C3 (0.45) ALDH1A1LMNAGAASMN1; SMN2HDAC1
SCHEMBL7680584 0.80 AKR1C3 (0.48) ALDH1A1LMNAGAASMN1; SMN2PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6436925-B1 BETTER ABLE TO CROSS MEMBRANES; INHIBITORS OF CYSTEINE PROTEASES LIKE CALPAIN I AND II AND CATHEPSIN B AND L, CAN THUS BE USED TO CONTROL DISEASES ASSOCIATED WITH AN ELEVATED ACTIVITY OF CALPAIN ENZYMES OR CATHEPSIN ENZYMES ABBOTT LABORATORIES 2002-08-20 US disclosed